Literature DB >> 11874860

T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy.

Alda Maria Da-Cruz1, Rita Bittar, Marise Mattos, Manuel P Oliveira-Neto, Ricardo Nogueira, Vanessa Pinho-Ribeiro, Rilza Beatriz Azeredo-Coutinho, Sergio G Coutinho.   

Abstract

T-cell immune responses in patients with cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML) were studied during the active disease, at the end of therapy, and 1 to 17 years posttherapy (long-term follow-up). Lymphocyte proliferative responses, phenotypic characterization of CD4(+) and CD8(+) Leishmania-reactive T cells, and cytokine production were assayed. Patients with active ML and CL showed higher proportions of CD4(+) than CD8(+) T cells. In CL, the healing process was associated with a decrease of CD4(+) and an increase of CD8(+), leading to similar CD4(+) and CD8(+) proportions. This pattern was only seen in ML after long-term therapy. Long-term follow-up of patients with CL showed a positive CD4(+)/CD8(+) ratio as observed during the active disease, although the percentages of these T cell subsets were significantly lower. Patients with CL did not show significant differences between gamma interferon (IFN-gamma) and interleukin-5 (IL-5) production during the period of study. Patients with active ML presented higher IFN-gamma and IL-5 levels compared to patients with active CL. IL-4 was only detected during active disease. Patients long term after cure from ML showed increasing production of IFN-gamma, significant decrease of IL-5, and no IL-4 production. Two apparently beneficial immunological parameters were detected in tegumentary leishmaniasis: (i) decreasing proportions of CD4(+) Leishmania-reactive T cells in the absence of IL-4 production associated with cure of CL and ML and (ii) decreasing levels of IL-5 long after cure, better detected in patients with ML. The observed T-cell responses maintained for a long period in healed patients could be relevant for immunoprotection against reinfection and used as a parameter for determining the prognosis of patients and selecting future vaccine preparations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874860      PMCID: PMC119941          DOI: 10.1128/cdli.9.2.251-256.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  32 in total

1.  Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment.

Authors:  V P Toledo; W Mayrink; K J Gollob; M A Oliveira; C A Costa ; O Genaro; J A Pinto; L C Afonso
Journal:  Mem Inst Oswaldo Cruz       Date:  2001-01       Impact factor: 2.743

2.  Quantitative study of Leishmania braziliensis braziliensis reactive T cells in peripheral blood and in the lesions of patients with American mucocutaneous leishmaniasis.

Authors:  F Conceição-Silva; R C Dórea; C Pirmez; A Schubach; S G Coutinho
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

3.  Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis.

Authors:  K Kemp; T G Theander; L Hviid; A Garfar; A Kharazmi; M Kemp
Journal:  Scand J Immunol       Date:  1999-06       Impact factor: 3.487

4.  Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.

Authors:  R L Bottrel; W O Dutra; F A Martins; B Gontijo; E Carvalho; M Barral-Netto; A Barral; R P Almeida; W Mayrink; R Locksley; K J Gollob
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection.

Authors:  S Ajdary; M H Alimohammadian; M B Eslami; K Kemp; A Kharazmi
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 6.  A review of the geographic distribution and epidemiology of leishmaniasis in the New World.

Authors:  G Grimaldi; R B Tesh; D McMahon-Pratt
Journal:  Am J Trop Med Hyg       Date:  1989-12       Impact factor: 2.345

7.  Cell mediated immunity in American cutaneous and mucosal leishmaniasis.

Authors:  E M Carvalho; W D Johnson; E Barreto; P D Marsden; J L Costa; S Reed; H Rocha
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

8.  T-cell subpopulations, expression of interleukin-2 receptor, and production of interleukin-2 and gamma interferon in human American cutaneous leishmaniasis.

Authors:  M Castes; M Cabrera; D Trujillo; J Convit
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

9.  Induction by specific T lymphocytes of intracellular destruction of Leishmania major in infected murine macrophages.

Authors:  S G Coutinho; J A Louis; J Mauel; H D Engers
Journal:  Parasite Immunol       Date:  1984-03       Impact factor: 2.280

10.  The relationship of Leishmania braziliensis subspecies and immune response to disease expression in New World leishmaniasis.

Authors:  N G Saravia; L Valderrama; M Labrada; A F Holguín; C Navas; G Palma; K A Weigle
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

View more
  50 in total

1.  Regulatory T-Cell Dynamics in Cutaneous and Mucocutaneous Leishmaniasis due to Leishmania braziliensis.

Authors:  Nicolas Barros; Nestor Vasquez; Fernando Woll; Cesar Sanchez; Braulio Valencia; Alejandro Llanos-Cuentas; A Clinton White; Martin Montes
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

2.  Effector memory CD4(+) T cells differentially express activation associated molecules depending on the duration of American cutaneous leishmaniasis lesions.

Authors:  C de Oliveira Mendes-Aguiar; R Vieira-Gonçalves; L H Guimarães; M P de Oliveira-Neto; E M Carvalho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2016-06-06       Impact factor: 4.330

3.  Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study.

Authors:  Marlene Jara; Braulio Mark Valencia; Vanessa Adaui; Milena Alba; Rachel Lau; Jorge Arevalo; Alejandro Llanos-Cuentas; Andrea K Boggild
Journal:  Am J Trop Med Hyg       Date:  2015-10-19       Impact factor: 2.345

4.  Immunoregulatory profile of monocytes from cutaneous leishmaniasis patients and association with lesion size.

Authors:  É L M Vieira; T S L Keesen; P R Machado; L H Guimarães; E M Carvalho; W O Dutra; K J Gollob
Journal:  Parasite Immunol       Date:  2013-02       Impact factor: 2.280

5.  Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response.

Authors:  S Farajnia; F Mahboudi; S Ajdari; N E Reiner; A Kariminia; M H Alimohammadian
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

6.  Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment.

Authors:  Luiza C Reis; Maria Edilenza F Brito; Marina A Souza; Angela C R Medeiros; Claudio J Silva; Carlos F Luna; Valéria R A Pereira
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

7.  CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Hossein Keshavarz; Rosita Edalat; Abdolfattah Sarrafnejad; Tahereh Shahrestani; Fereidoun Mahboudi; Ali Khamesipour
Journal:  PLoS Negl Trop Dis       Date:  2010-10-12

8.  Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil.

Authors:  Alon Unger; Seth O'Neal; Paulo R L Machado; Luiz H Guimarães; Daniel J Morgan; Albert Schriefer; Olívia Bacellar; Marshall J Glesby; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

9.  Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?

Authors:  A Gomes-Silva; R de Cássia Bittar; R Dos Santos Nogueira; V S Amato; M da Silva Mattos; M P Oliveira-Neto; S G Coutinho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

10.  CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis.

Authors:  R Jafari-Shakib; S Ajdary; Z Mohtasham Amiri; A M Mohammadi; K Nourijelyani; H Mortazavi; M A Shokrgozar; B Nikbin; A Khamesipour
Journal:  Clin Exp Immunol       Date:  2008-05-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.